Literature DB >> 24150752

Early over-expression of GRP receptors in prostatic carcinogenesis.

Meike Körner1, Beatrice Waser, Ruth Rehmann, Jean Claude Reubi.   

Abstract

BACKGROUND: The GRP receptor shows high over-expression in prostatic adenocarcinoma and high grade PIN, but low expression in normal prostate glands. This represents the molecular basis for GRP receptor imaging of prostate cancer with radioactive compounds. However, a focal, high density GRP receptor expression can be observed in hitherto uncharacterized prostate glands.
METHODS: GRP receptors were quantitatively measured with in vitro receptor autoradiography using ¹²⁵I-Tyr⁴ -bombesin in samples from 115 prostates. On successive tissue sections, ¹²⁵I-Tyr⁴ -bombesin autoradiography was compared with H&E staining and MIB-1 and 34βE12 immunohistochemistry.
RESULTS: On one hand, it was confirmed that GRP receptors were expressed in adenocarcinoma and high grade PIN in high density and high incidence (77% and 73%, respectively), but in normal prostate glands in low density and low frequency (18%). On the other hand, a novel and intriguing observation was the existence of focal non-invasive prostate glands with high GRP receptor density, characterized by low grade nuclear atypia and increased proliferation, compatible with lower grade PIN. There was a significant GRP receptor density gradient (P ≤ 0.005), increasing from normal prostate glands (mean relative optical density, ROD, of ¹²⁵I-Tyr⁴ -bombesin binding: 0.17) over atypical glands without increased MIB-1 labeling (0.28) and atypical glands with increased MIB-1 expression (0.44) to high grade PIN and adenocarcinoma (0.64 and 0.58, respectively).
CONCLUSIONS: GRP receptor over-expression may be a novel, specific marker of early prostatic neoplastic transformation, arising in low grade PIN, and progressively increasing during malignant progression. This should be considered when interpreting in vivo GRP receptor imaging in males.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  GRP receptor; bombesin receptor; in vitro receptor autoradiography; prostate cancer; prostatic intraepithelial neoplasia

Mesh:

Substances:

Year:  2013        PMID: 24150752     DOI: 10.1002/pros.22743

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  11 in total

1.  Easy formulation of liposomal doxorubicin modified with a bombesin peptide analogue for selective targeting of GRP receptors overexpressed by cancer cells.

Authors:  Antonella Accardo; Silvia Mannucci; Elena Nicolato; Federica Vurro; Carlo Diaferia; Pietro Bontempi; Pasquina Marzola; Giancarlo Morelli
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

Review 2.  Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment.

Authors:  Paola Moreno; Irene Ramos-Álvarez; Terry W Moody; Robert T Jensen
Journal:  Expert Opin Ther Targets       Date:  2016-03-28       Impact factor: 6.902

Review 3.  [Focus on molecular imaging in prostate cancer].

Authors:  L Michaud; K A Touijer
Journal:  Prog Urol       Date:  2016-09-20       Impact factor: 0.915

4.  Gastrin-releasing peptide receptor (GRPr) promotes EMT, growth, and invasion in canine prostate cancer.

Authors:  Said M Elshafae; Bardes B Hassan; Wachiraphan Supsavhad; Wessel P Dirksen; Rachael Y Camiener; Haiming Ding; Michael F Tweedle; Thomas J Rosol
Journal:  Prostate       Date:  2016-03-04       Impact factor: 4.104

Review 5.  Prostate cancer relevant antigens and enzymes for targeted drug delivery.

Authors:  Ashutosh Barve; Wei Jin; Kun Cheng
Journal:  J Control Release       Date:  2014-05-27       Impact factor: 9.776

6.  Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.

Authors:  Theodosia Maina; Hendrik Bergsma; Harshad R Kulkarni; Dirk Mueller; David Charalambidis; Eric P Krenning; Berthold A Nock; Marion de Jong; Richard P Baum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12-02       Impact factor: 9.236

7.  NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [67Ga]NeoBOMB1 in T-47D Cells and Tumor-Bearing Mice.

Authors:  Aikaterini Kaloudi; Emmanouil Lymperis; Athina Giarika; Simone Dalm; Francesca Orlandi; Donato Barbato; Mattia Tedesco; Theodosia Maina; Marion de Jong; Berthold A Nock
Journal:  Molecules       Date:  2017-11-11       Impact factor: 4.411

8.  Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression.

Authors:  Jingbo Qiao; Magdalena M Grabowska; Ingrid S Forestier-Roman; Janni Mirosevich; Thomas C Case; Dai H Chung; Justin M M Cates; Robert J Matusik; H Charles Manning; Renjie Jin
Journal:  Oncotarget       Date:  2016-09-20

9.  Voxel-based comparison of [68Ga]Ga-RM2-PET/CT and [68Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer.

Authors:  Thomas Franz Fassbender; Florian Schiller; Constantinos Zamboglou; Vanessa Drendel; Selina Kiefer; Cordula A Jilg; Anca-Ligia Grosu; Michael Mix
Journal:  EJNMMI Res       Date:  2020-06-12       Impact factor: 3.138

10.  [99mTc]Tc-DB1 Mimics with Different-Length PEG Spacers: Preclinical Comparison in GRPR-Positive Models.

Authors:  Panagiotis Kanellopoulos; Emmanouil Lymperis; Aikaterini Kaloudi; Marion de Jong; Eric P Krenning; Berthold A Nock; Theodosia Maina
Journal:  Molecules       Date:  2020-07-28       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.